Weekly newsletter

A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYEI), the institute said on Saturday.

The licence was issued in an expedited procedure.

The drug, which Egis started developing in April, could be used to treat coronavirus patients from mid-January.

'Remdesivir is Clearly Helping People' - Interview with Richter CEO Gábor Orbán
'Remdesivir is Clearly Helping People' - Interview with Richter CEO Gábor Orbán

“Remdesivir can cut the duration of hospital stay by 3-5 days,” Gábor Orbán, CEO of major Hungarian pharmaceutical company Gedeon Richter, told Hungary Today in an exclusive interview. Orbán discussed the pandemic, the drug remdesivir, the issue of vaccination and social trust, and what we learnt from the crisis. When did you first hear about […]Continue reading

Favipiravir is the second drug, after remdesivir, that has been licenced by the OGYEI to treat Covid-19 patients.

featured image illustration (Egis’ lab in Körmend) via Facebook